Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027.
SELLAS Life Sciences Group (NASDAQ: SLS) shares surged 240% after the biotechnology company announced positive topline results from its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an investigational cancer vaccine targeting acute myeloid leukemia (AML).
The trial successfully met its primary endpoint of overall survival, demonstrating a 41% reduction in the risk of death compared with best available treatment. Patients receiving GPS achieved a median overall survival of 24.0 months, significantly exceeding the 14.7 months observed in the control group.
The study focused on AML patients who achieved a second or later complete remission but were ineligible for, or unable to undergo, stem cell transplantation.
GPS also demonstrated a favorable safety profile, with no new safety concerns identified. Most treatment-related adverse events were mild to moderate, primarily involving injection-site reactions.
Following the encouraging results, SELLAS plans to engage with the U.S. Food and Drug Administration to discuss an accelerated regulatory filing strategy, targeting a Biologics License Application submission during the first half of 2027.
Additional trial analyses are underway, with comprehensive findings expected to be presented at an upcoming medical conference and submitted for peer-reviewed publication.









